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Abstract 80 
Background: Except for a documented increase in osteoprotegerin (OPG) concentrations with 81 
older age, data on determinants of soluble Receptor Activator of Nuclear Factor κB (sRANKL) 82 
and OPG concentrations in women are limited. We evaluated reproductive and lifestyle factors 83 
as potential sources of variation in circulating sRANKL and OPG concentrations in pre- and 84 
postmenopausal women. 85 
Methods: This study includes 2016 controls (n=1552 (76%) postmenopausal, n=757 (38%) 86 
using postmenopausal hormone therapy (PMH)) from a breast cancer case-control study nested 87 
in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Serum 88 
sRANKL was measured using an enzyme-linked immunosorbent assay, serum OPG using an 89 
electrochemiluminescent assay. Generalized linear models were used to evaluate associations 90 
between these analytes and reproductive and lifestyle factors. 91 
Results: Older age at blood collection was associated with lower sRANKL concentrations in 92 
postmenopausal women (ptrend≤0.03) and higher OPG concentrations in all women (ptrend≤0.01). 93 
Longer duration of OC use among premenopausal women and postmenopausal PMH users 94 
was associated with higher OPG (ptrend≤0.04). In postmenopausal non-PMH users, sRANKL 95 
concentrations were lower with longer duration of OC use and current (vs. never) smoking 96 
(p≤0.01). sRANKL concentrations were higher among women with higher BMI (ptrend≤0.01). The 97 
evaluated factors accounted for 12% of the variation in sRANKL concentrations and 21% of the 98 
variation in OPG concentrations. 99 
Conclusion: Circulating sRANKL and OPG concentrations are minimally impacted by hormone-100 
related factors in pre- and postmenopausal women. 101 
Impact: This study suggests circulating concentrations of sRANKL and OPG are unlikely to be 102 
strongly modified by hormone-related reproductive and lifestyle factors. 103 
 104 
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Introduction 106 
The Receptor Activator of Nuclear Factor κB (RANK) axis includes the receptor, its ligand 107 
(RANKL) and the decoy receptor for RANKL, osteoprotegerin (OPG). Studies in experimental 108 
animal models have shown that the RANK-axis plays an important role in a number of 109 
processes including bone turnover, immune response, cardiovascular disease, and breast 110 
development in pregnancy, as well as development and progression of breast cancer [1-3]. With 111 
respect to breast cancer, we [4-6] and others [7-10] have observed associations between 112 
circulating concentrations of RANK-axis members and breast cancer risk and prognosis. 113 
Following development of an antibody for RANKL, denosumab, there is increasing interest in 114 
RANKL and OPG in relation to breast cancer prevention and treatment.  115 
Given the relevance of the RANK-axis for a variety of outcomes, understanding whether 116 
concentrations of sRANKL (the soluble homotrimeric form of RANKL found in circulation) and 117 
OPG are potentially modulated by lifestyle and reproductive factors is of interest. Characterizing 118 
these associations contributes toward informing mechanistic understanding of associations 119 
between these factors and disease risk, providing an indication as to whether a subgroup of 120 
women may have particularly high concentrations due to lifestyle and/or reproductive-related 121 
factors, and elucidating whether circulating concentrations may be modifiable via changes in 122 
lifestyle and reproductive-related exposures. However, data to date on correlates of sRANKL 123 
and OPG concentrations in healthy individuals are limited. In a study of twins, genetic factors 124 
explained half of the variation in sRANKL concentrations, whereas OPG concentrations were 125 
almost entirely determined by environmental factors including age [11]. A positive correlation 126 
between age and OPG concentrations has been reported by a number of studies [11-14], 127 
including our own (e.g., Spearman correlation=0.29) [5]. We have also previously reported that 128 
OPG concentrations were higher among ever users of oral contraceptives (OCs) [5]. Given 129 
interest in circulating OPG and sRANKL for multiple disease outcomes, and following our prior 130 
observation of differences in OPG [5] and sRANKL [6] concentrations depending on 131 
postmenopausal hormone (PMH) use at blood collection, we conducted a detailed evaluation of 132 
associations between sRANKL and OPG concentrations and hormone-related reproductive and 133 
lifestyle factors in women by menopausal status and PMH use at blood collection.  134 
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Materials and methods 136 
Study population 137 
The participants included in this study were women selected as controls in a case-control study 138 
on sRANKL and OPG concentrations and breast cancer risk (n=2023) nested within the 139 
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Data on 140 
reproductive, lifestyle and anthropometric characteristics were collected for EPIC participants at 141 
baseline. Detailed descriptions of data collection with the EPIC cohort and design and baseline 142 
characteristics of the parent case-control study have been described in detail previously [5, 6, 143 
15]. For the current study, eligible women were selected among cohort members who donated a 144 
baseline blood sample and were alive and free of cancer (except non-melanoma skin cancer) at 145 
the time of diagnosis of their index case. Premenopausal women were eligible if they were not 146 
using exogenous hormones at baseline. 147 
Laboratory assays 148 
Serum concentrations of sRANKL and OPG were analyzed at the laboratory of the Division of 149 
Cancer Epidemiology at the German Cancer Research Center (DKFZ).  Total OPG 150 
concentrations were measured using an electrochemiluminescence assay (MesoScale 151 
Diagnostics, USA), a volume-efficient alternative to an enzyme-linked immunosorbent assay 152 
(ELISA). Free (i.e. non-OPG bound, or bioavailable) sRANKL concentrations were measured 153 
using an ELISA (Biomedica, Austria). The majority of sRANKL in circulation is bound to OPG 154 
and free sRANKL concentrations are known to be low [16]; free sRANKL concentrations in our 155 
study were below the lower limit of detection of the assay (LLOD) in 152 women and were set to 156 
50% of the LLOD (0.01 picomole per liter (pmol/L)). Due to equipment failure two batches (38 157 
women) of samples were not measured for sRANKL. A total of 4 women were missing sRANKL 158 
and/or OPG concentrations, leaving a total of 1981 women with sRANKL and 2019 women with 159 
OPG measured (Figure 1). Inter-batch coefficients of variation (CVs) were 15.6% for 160 
premenopausal and 13.3% in postmenopausal women for sRANKL and 16.4% and 16.8%, 161 
respectively, for OPG. Intra-batch CVs were 0.9% and 1.5% for sRANKL in pre- and 162 
postmenopausal women, and 9.0% and 21.7% for OPG. 163 
Statistical analyses 164 
Outliers were evaluated using the extreme studentized deviate test [17]; three women with 165 
outlying OPG concentrations (two with high concentrations and one with low concentrations) 166 
were identified and excluded (Figure 1). No sRANKL outliers were identified. Means of natural 167 
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log-transformed sRANKL and OPG concentrations were compared between categories of 168 
reproductive and lifestyle factors using adjusted generalized linear models. These results were 169 
exponentiated, providing the geometric mean in the original scale. Confidence limits were 170 
calculated subtracting/adding the standard error multiplied by 1.96 (corresponding to the α for a 171 
two-sided p value of 0.05) from the geometric mean. P values for differences in concentrations 172 
across categories were calculated using Type III sum of squares; ptrend was calculated by 173 
modelling the continuous variable as the exposure.  174 
We evaluated age at blood collection (<50, 50-54, 55-59, 60+ years), age at menarche (<12, 175 
12-14, 15+ years), oral contraceptive use (never, <5, 5-9, 10+ years), number of term 176 
pregnancies (none, 1, 2, 3+) and age at first term pregnancy among women reporting ≥1 177 
pregnancies (<25, 25+ years), body mass index (BMI; <20, 20-24.9, 25-29.9, 30+ kg/m2), 178 
smoking status (never, former, current) and duration of smoking among ever smokers (≤10, 11-179 
20, 21-30, 31-40, 41+ years), and total physical activity (inactive, moderately inactive, 180 
moderately active, active). The total physical activity variable includes household, recreational 181 
and occupational activity, as previously described [18, 19]. Additional variables of interest were 182 
ever breastfeeding and duration of breastfeeding among parous women reporting ever 183 
breastfeeding (<3, 3-6, 6-12, 12+ months), lifetime average alcohol consumption (never drinker, 184 
former drinker, >0-6, >6-12, >12 grams/day), and fasting status at blood collection (<3, 3-6, 7+ 185 
hours). All analyses adjusted for the matching factors from the parent case-control study: 186 
country (as a proxy for study center), age (continuous), menstrual cycle phase (premenopausal 187 
women; early follicular, late follicular, ovulatory, early luteal, mid luteal, late luteal, missing; 188 
estimated using “backward dating” counting backward from start of menses following blood 189 
collection where data were available, otherwise estimated using “forward dating” as time since 190 
last menses (described in detail in [20]), fasting status (<3, 3-6, 7+ hours, missing), and time at 191 
blood collection (continuous), except when the variable was the exposure of interest. In a 192 
sensitivity analysis, OC use and smoking status were mutually adjusted. Given our previous 193 
observation that sRANKL concentrations were lower [6], and OPG concentrations higher [5], 194 
among postmenopausal women using PMH, models were stratified by menopausal status and 195 
PMH use at blood collection. OPG and sRANKL concentrations did not vary by menstrual cycle 196 
phase in premenopausal women [5, 6]. We estimated the proportion of variance explained by 197 
the epidemiological factors using the linear regression model R-squared value. 198 
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Inclusion of participants with sRANKL values below the LLOD of the assay led to a non-normal 199 
distribution of sRANKL concentrations; these subjects were excluded in a sensitivity analysis. 200 
All statistical tests were two-tailed and significant at p<0.05. Statistical analyses were conducted 201 
using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). 202 
Results 203 
Lower circulating sRANKL concentrations were observed with older age among women 204 
postmenopausal at blood collection (ptrend ≤0.03; Table 1). There was no difference in 205 
concentrations by age among premenopausal women (ptrend 0.20); however, the range in age 206 
was limited in this subgroup. In postmenopausal women not using PMH, both ever use of OCs 207 
and longer duration of OC use among ever users were associated with lower sRANKL 208 
concentrations (p ≤0.01). Among postmenopausal PMH users who ever used OCs, longer 209 
duration of use was suggestively inversely associated with sRANKL concentrations (ptrend 0.07). 210 
Parity (p ≥0.18), and ages at menarche (pcat ≥0.14) and first full term pregnancy (pcat ≥0.19) 211 
were not associated with sRANKL concentrations.  212 
A higher BMI was associated with higher sRANKL concentrations regardless of menopausal 213 
status and PMH use at blood collection (ptrend ≤0.01; Table 2). In postmenopausal women not 214 
using PMH at blood collection, there was suggestion of lower sRANKL concentrations in current 215 
smokers than in never smokers (pcat 0.09; Table 2); among women using PMH at blood 216 
collection current smokers had significantly lower sRANKL concentrations relative to never 217 
smokers (pcat 0.01). The associations between OC use and smoking and sRANKL 218 
concentrations were robust to mutual adjustment (data not shown). We found no association 219 
between alcohol consumption and sRANKL concentrations (p ≥0.22). 220 
Overall, the epidemiological factors found to be associated with circulating sRANKL 221 
concentrations (plus the matching factors) explained 12% of the variability in this analyte in the 222 
full population; each individual variable explained <6% of the variation in sRANKL 223 
concentrations. Results were unchanged after excluding participants with sRANKL 224 
concentrations below the LLOD (Supplemental tables 1 and 2).  225 
OPG concentrations were highest among women with older age at blood collection (ptrend ≤0.01; 226 
Table 3). Longer duration of OC use was associated with higher OPG concentrations in 227 
premenopausal women (ptrend 0.04) and postmenopausal women using PMH (ptrend <0.01) in 228 
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analyses including never OC users. The association in premenopausal women was no longer 229 
statistically significant after adjustment for smoking (ptrend 0.06; data not tabled), while the 230 
association was robust to this adjustment in postmenopausal women using PMH (ptrend <0.01). 231 
No significant trend was observed in analyses restricted to ever users of OCs. Parity (pcat ≥0.13) 232 
and ages at menarche (pcat 0.16) and first full term pregnancy (pcat ≥0.11) were not associated 233 
with OPG concentrations (Table 3); neither were any of the investigated lifestyle factors (p 234 
≥0.09; Table 4). Overall, the epidemiological factors found to be associated with circulating 235 
OPG concentrations (plus the matching factors) explained 21% of the variability. The majority of 236 
this variability in OPG concentrations (18%) was explained by age.  237 
In further analyses fasting status (ptrend ≥0.15), breastfeeding history (pcat 0.17), and menstrual 238 
cycle phase (pcat ≥0.18) did not influence sRANKL or OPG concentrations (Supplemental 239 
tables 3, 4, and 5). Among premenopausal parous women who breastfed, a longer duration of 240 
breastfeeding was associated with lower sRANKL concentrations (ptrend ≤0.03; Supplemental 241 
tables 3 and 4). 242 
Discussion 243 
We provide a large-scale cross-sectional study on reproductive and lifestyle factors in relation to 244 
sRANKL and OPG concentrations in healthy women. Our study suggests that circulating 245 
concentrations of these biomarkers are not strongly impacted by these characteristics. This 246 
study extends our prior work, where we reported Spearman correlations between sRANKL and 247 
OPG concentrations and circulating sex hormones, and age and BMI [5, 6]; here we evaluated 248 
geometric mean concentrations for an extensive selection of epidemiologic characteristics, and 249 
assessed the total variance explained by these characteristics, to inform future studies 250 
incorporating these analytes. 251 
RANKL is highly expressed in bone, lung and lymph nodes and is found at lower levels in 252 
tissues including the placenta and heart [21]. Circulating sRANKL is cleaved from RANKL 253 
expressed in tissue by metalloproteinases or formed by alternative messenger ribonucleic acid 254 
(mRNA) splicing [3]. The RANK-axis is an essential mediator of progesterone-induced 255 
proliferation in the breast during pregnancy in preparation for the formation of a lactating gland 256 
[22, 23]. In addition to progesterone, prolactin and parathyroid hormone-related peptide, but not 257 
estradiol, have been shown to induce RANKL expression in mouse mammary tissue [24-28]. 258 
While the main sources of circulating OPG appear to be bone marrow and vascular endothelial 259 
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cells [29, 30], it is also produced by osteoblasts and production of OPG in the latter may be 260 
upregulated by estrogen and vitamin D, but not progesterone [13, 30-34].  261 
OPG concentrations are known to increase with age [12, 13, 35], which was confirmed in our 262 
study. In line with our findings, weak inverse associations between age and sRANKL have been 263 
reported [6, 36, 37], with Spearman correlations < |0.13| observed in the current study 264 
population [6]; however, the associations observed between age and sRANKL concentrations in 265 
prior studies are not entirely consistent and weak positive [38, 39] and null findings [36] have 266 
also been reported. Longer duration of OC use was associated with lower concentrations of 267 
sRANKL, and higher concentrations of OPG; the associations for sRANKL and for OPG among 268 
postmenopausal women not using PMH were robust to adjustment for smoking, while the OPG 269 
associations for premenopausal women were attenuated (p 0.06 after adjustment; p 0.04 before 270 
adjustment). Prior studies have reported positive associations between current OC use and 271 
OPG concentrations, unadjusted for smoking, but no association for sRANKL [40, 41]. To our 272 
knowledge there are no prior studies on duration of OC use and circulating sRANKL or OPG. It 273 
is plausible prolonged exposure to estrogens in OCs could increase OPG concentrations (and in 274 
turn lower free sRANKL concentrations), yet a mechanistic study did not observe changes in 275 
serum sRANKL or OPG in macaque monkeys after estrogen and progesterone treatment [42]. 276 
Among the relatively small subset of parous women who ever breastfed (n=332), longer 277 
duration of breastfeeding was associated with lower sRANKL concentrations. While the RANK-278 
RANKL signaling is essential for breast development in pregnancy, we are not aware of any 279 
studies describing the role of the RANK-axis in prolonged breastfeeding. 280 
We observed higher concentrations of sRANKL with higher BMI, regardless of menopausal 281 
status at blood collection. While Uemura et al. observed no association between sRANKL and 282 
BMI in a population of postmenopausal women [39], others have reported a positive association 283 
with BMI in populations of men and women [43] and adolescents [44], as well as positive 284 
correlations between sRANKL and obesity-related markers of inflammation and insulin 285 
resistance [43]. In line with previous studies [12, 39, 45, 46], OPG concentrations were similar 286 
across BMI categories in the current study. Our finding of an inverse association between 287 
current smoking and sRANKL concentrations among postmenopausal women using PMH, and 288 
duration of smoking and sRANKL concentrations among postmenopausal women not using 289 
PMH is in agreement with prior studies in women [40] and a population of men and women [47]. 290 
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No associations were observed between any of the investigated reproductive factors and 291 
sRANKL or OPG concentrations. For sRANKL in particular, this may be reflective of weak 292 
associations between concentrations in the breast and circulating concentrations, as 293 
demonstrated by a previous study in macaques [42]. In addition, we have shown that, though 294 
concentrations of OPG were reproducible over time (Spearman r for serum samples taken 295 
fourteen years apart: 0.75), long-term reproducibility of sRANKL was lower (Spearman r: 0.38). 296 
This indicates one measurement of sRANKL may not reflect longer-term exposure [5, 6]. While 297 
we observed no associations between hormone-related factors and circulating sRANKL and/or 298 
OPG among women predominantly older than age 50 in the current study, it is plausible that 299 
these reproductive factors may impact concentrations in the shorter term, but may not be 300 
evident in the longer term, following these reproductive events. 301 
At the time we initiated our study, there were no previous studies on sRANKL or OPG and 302 
breast cancer, which was the focus of the parent study. Three studies published since used 303 
ELISA assays to measure OPG concentrations [7, 8, 42]. The two studies that report OPG 304 
concentrations observed different ranges of OPG concentrations in their study populations: 305 
0.46-25.81 ng/ml (23.12-1296.98pmol/L; [7]) and 4.2-547.7ng/mL (211.06-27522.61pmol/L; [8]), 306 
however, the two studies used different ELISAs. Both of these reported concentrations are 307 
higher than the range of concentrations we observed in the current study (3.54-33.02pmol/L). 308 
Given the lack of a cross-assay standardization protocol, comparison   between studies relies 309 
on relative within-study differences in concentrations. The ELISA we used to quantify free 310 
sRANKL concentrations in our study is the most sensitive assay currently commercially 311 
available, but median free sRANKL concentrations observed in our study were relatively low 312 
(0.11 pmol/L) and 7.5% (n=152) of the study population had concentrations below the LLOD of 313 
the assay. One previous study used the same assay to measure sRANKL, but did not report 314 
mean or median concentrations, or if any samples were measured to be below the LLOD [9]. 315 
Total serum sRANKL concentrations may be over 1000pmol/L, but the majority of sRANKL 316 
found in circulation is bound to OPG [16] and cannot bind to RANK to activate signaling. Thus, 317 
even though free sRANKL concentrations are low, they are likely a more informative measure 318 
than total sRANKL concentrations.   319 
A further limitation to our study is the relatively high inter-batch CVs, especially for OPG 320 
concentrations in postmenopausal women, indicating potential measurement error that may 321 
have attenuated findings. In addition,  one small previous study suggests sRANKL and OPG 322 
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concentrations may decrease over time in serum samples stored at temperatures higher than -323 
70ºC [48]. Serum samples in our study were stored at -150ºC and we observed no correlation 324 
between sRANKL and OPG concentrations and date of blood collection (Spearman r ≤0.03; 325 
samples collected between 1992 and 2002). R squared values indicate that the evaluated 326 
factors explain relatively little of the variation in sRANKL and OPG concentrations. However, 327 
this may be influenced by the limited variability in the distributions of the examined factors in our 328 
population of middle to older aged European women. Finally, due to multiple comparisons, 329 
some of our results may be due to chance. 330 
In this large cross-sectional study, we demonstrate that circulating sRANKL and OPG 331 
concentrations are minimally impacted by hormone-related factors in women. In the context of 332 
the limited evidence to date, these results suggest circulating concentrations of sRANKL and 333 
OPG are unlikely to be modifiable by lifestyle or reproductive factors. 334 
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Table 1. Cross-sectional associations between reproductive characteristics and sRANKL concentrations (geometric means; pmol/L) by menopausal 
status and PMH use at blood collection. 
 
Premenopausal women  
Postmenopausal women  
 No PMH  PMH  
 n (%)
a Geometric mean 
(95%CI) 
n (%)
a Geometric mean 
(95%CI) 
n (%)
a Geometric mean 
(95%CI) 
Full study population* 463 (100%) 0.07 (0.06-0.08) 760 (100%) 0.08 (0.07-0.10) 758 (100%) 0.06 (0.05-0.08) 
Age at blood collection, years       
<50 370 (80%) 0.10 (0.08-1.13) 12 (2%) 0.09 (0.05-0.17) 31 (4%) 0.10 (0.06-0.17) 
50-55 90 (19%) 0.08 (0.06-1.12) 123 (16%) 0.10  (0.07-0.12) 194 (26%) 0.08  (0.06-0.10) 
50-60 3 (1%) ǂ 279 (37%) 0.08 (0.06-0.09) 309 (41%) 0.07  (0.05-0.09) 
60+   346 (46%) 0.07 (0.06-0.09) 224 (30%) 0.06 (0.04-0.08) 
Ptrend
b
  0.20  <0.01  0.03 
Age at menarche, years       
     <12  80 (17%) 0.11 (0.08-0.15) 101 (13%) 0.09 (0.07-0.12) 120 (16%) 0.06 (0.04-0.08) 
     12-14  321 (69%) 0.10 (0.08-0.12) 489 (64%) 0.08 (0.07-0.10) 484 (64%) 0.07 (0.06-0.09) 
     ≥15  59 (13%) 0.08 (0.06-0.11) 159 (21%) 0.07 (0.05-0.09) 146 (19%) 0.07 (0.05-0.09) 
Ptrend
b
  0.16  0.14  0.93 
Oral contraceptive (OC) use       
     Never 165 (37%) 0.10 (0.08-0.13) 473 (65%) 0.08 (0.07-0.10) 282 (41%) 0.07 (0.05-0.09) 
          < 5 years 157 (35%) 0.09 (0.07-0.12) 158 (18%) 0.09 (0.07-0.11) 164 (24%) 0.09 (0.06-0.12) 
          5-9 years 75 (17%) 0.10 (0.07-0.14) 50 (7%) 0.07 (0.05-0.10) 78 (11%) 0.06 (0.04-0.09) 
          ≥ 10 years 49 (11%) 0.07 (0.05-0.10) 79 (11%) 0.06 (0.04-0.07) 169 (24%) 0.07 (0.05-0.09) 
Ptrend
c
 including never users  0.08  <0.01  0.28 
Ptrend
bd
 among ever users
 
 0.34  0.01  0.07 
Full-term pregnancy (FTP)       
     Never 56 (12%0 0.10 (0.07-0.14) 95 (13%) 0.08 (0.06-0.10) 89 (12%) 0.06 (0.04-0.08) 
     Ever 401 (87%) 0.10 (0.08-0.13) 663 (87%) 0.08 (0.06-0.10) 647 (85%) 0.07 (0.05-0.09) 
          1 FTP
 
85 (21%) 0.10 (0.07-0.14) 109 (16%) 0.07 (0.05-0.09) 120 (19%) 0.06 (0.04-0.08) 
          2 FTPs
 
217 (54%) 0.10 (0.07-0.14) 308 (46%) 0.08 (0.06-0.10) 316 (49%) 0.07 (0.06-0.10) 
          ≥ 3 FTPs 98 (24%) 0.09 (0.07-0.13) 246 (37%) 0.08 (0.06-0.10) 210 (32%) 0.07 (0.05-0.10) 
Pcat
c
 ever/never   0.77  0.76  0.21 
Pcat
ce 
number
 
 0.90  0.60  0.18 
Age at first FTP
e
       
     < 25 years 192 (48%) 0.10 (0.07-0.13) 308 (46%) 0.08 (0.06-0.10) 369 (57%) 0.07 (0.05-0.09) 
     ≥ 25 years 207 (52%) 0.10 (0.07-0.13) 353 (53%) 0.07 (0.06-0.09) 272 (42%) 0.07 (0.05-0.09) 
Ptrend
b
  0.87  0.30  0.19 
a
 percentages may not add up to 100% due to missing data; 
b
 P value for linear trend assessed using type III F statistics from linear regression models with continuous exposure 
variables; 
c
 P value for difference in geometric mean concentration of OPG across categories of the exposure variable. Assessed using type III F statistics from linear regression models; 
d
 among those who ever used OCs; 
e
 Among those who ever had a FTP; ǂ Not evaluated; Generalized linear models adjusted for: age (continuous), fasting status ((<3, 3-6, >6 hours, 
missing), time of day (continuous), and menstrual cycle phase at blood collection (premenopausal women: early follicular, late follicular, ovulatory, early luteal, mid luteal, late luteal, 
missing), and country.* P value comparing pre- to postmenopausal at blood collection=0.91; comparing PMH to no PMH use at blood collection <0.01. 
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Table 2. Cross-sectional associations between lifestyle characteristics and sRANKL concentrations (geometric means; pmol/L) by menopausal status 
and PMH use at blood collection. 
 
Premenopausal women  
Postmenopausal women  
 No PMH  PMH  
 n (%)
a Geometric mean 
(95%CI) 
n (%)
a Geometric mean 
(95%CI) 
n (%)
a Geometric mean 
(95%CI) 
Baseline BMI       
    < 20  kg/m
2
 29 (6%) 0.07 (0.05-0.11) 48 (6%) 0.06 (0.04-0.09) 64 (8%) 0.06 (0.04-0.09) 
     20-24.9  kg/m
2
 252 (54%) 0.09 (0.07-0.11) 322 (42%) 0.07 (0.06-0.09) 426 (56%) 0.06 (0.04-0.08) 
     25-29.9  kg/m
2
 137 (30%) 0.11 (0.08-0.14) 285 (38%) 0.08 (0.07-0.11) 215 (28%) 0.09 (0.07-0.12) 
    ≥ 30  kg/m
2
 45 (10%) 0.13 (0.09-0.19) 105 (14%) 0.09 (0.07-0.12) 53 (7%) 0.10 (0.07-0.15) 
Ptrend
b 
 <0.01  0.01  <0.01 
Baseline smoking status       
     Never smoker 245 (53%) 0.10 (0.08-0.13) 435 (57%) 0.08 (0.07-0.10) 395 (52%) 0.08 (0.06-0.10) 
     Former smoker 110 (52%) 0.10 (0.07-0.13) 178 (56%) 0.08 (0.06-0.10) 199 (59%) 0.06 (0.05-0.08) 
     Current smoker 103 (48%) 0.08 (0.06-0.11) 140 (44%) 0.07 (0.05-0.09) 138 (41%) 0.05 (0.04-0.08) 
≤ 10 years
c 
45 (21%) 0.12 (0.08-0.19) 41 (13%) 0.08 (0.05-0.13) 55 (16%) 0.05 (0.03-0.08) 
11-20 years
c 
62 (29%) 0.12 (0.08-0.18) 44 (14%) 0.05 (0.03-0.07) 50 (15%) 0.06 (0.03-0.11) 
21-30 years
c 
87 (41%) 0.10 (0.07-0.15) 67 (21%) 0.08 (0.05-0.11) 73 (22%) 0.08 (0.05-0.13) 
31-40 years
c 
13 (6%) 0.07 (0.04-0.14) 90 (28%) 0.07 (0.05-0.11) 95 (28%) 0.04 (0.03-0.07) 
> 40 years
c 
0 ǂ 58 (18%) 0.06 (0.04-0.09) 41 (12%) 0.05 (0.03-0.10) 
Pcat
d 
never vs. current smoking  0.15  0.09  0.01 
Ptrend
bc 
duration of smoking
 
 0.15  0.65  0.58 
Baseline physical activity       
     Inactive 75 (16%) 0.09 (0.07-0.12) 80 (11%) 0.07 (0.05-0.10) 148 (20%) 0.07 (0.05-0.10) 
     Moderately inactive 145 (31%) 0.11 (0.08-0.14) 241 (32%) 0.07 (0.06-0.09) 319 (42%) 0.07 (0.06-0.10) 
     Moderately active 193 (42%) 0.09 (0.06-0.11) 381 (50%) 0.08 (0.07-0.10) 231 (30%) 0.07 (0.05-0.09) 
     Active 50 (11%) 0.09 (0.06-0.12) 58 (8%) 0.07 (0.05-0.10) 59 (8%) 0.07 (0.04-0.10) 
Pcat
c 
inactive vs. active  0.95  0.89  0.62 
Lifetime alcohol consumption       
   Non-drinker 40 (9)% 0.10 (0.07-0.16) 79 (10%) 0.08 (0.06-0.11) 27 (4%) 0.06 (0.03-0.10) 
   Former drinker 15 (3%) 0.08 (0.04-0.14) 41 (5%) 0.05 (0.04-0.08) 12 (2%) 0.07 (0.03-0.14) 
   Current drinker 395 (87%) 0.10 (0.08-0.14) 639 (81%) 0.08 (0.06-0.10) 696 (94%) 0.07 (0.05-0.09) 
      < 6 gram/day
e 
144 (32%) 0.10 (0.07-0.14) 216 (28%) 0.08 (0.06-0.10) 181 (24%) 0.07 (0.05-0.09) 
      6-12 gram/day
e 
168 (37%) 0.11 (0.08-0.15) 295 (39%) 0.08 (0.06-0.11) 337 (45%) 0.07 (0.05-0.10) 
      ≥12 gram day
e 
83 (18%) 0.09 (0.06-0.13) 110 (14%) 0.08 (0.06-0.10) 179 (24%) 0.06 (0.05-0.09) 
Pcat
d
 never vs. current alcohol use  0.94  0.86  0.46 
Ptrend
b
 gram/day
e 
 0.81  0.87  0.53 
a
 percentages may not add up to 100% due to missing data; 
b
 P value for linear trend assessed using type III F statistics from linear regression models with continuous exposure variables; 
c
 
Among current and former smokers; 
d
 P value for difference in geometric mean concentration of sRANKL across categories of the exposure variable. Assessed using type III F statistics 
from linear regression models; 
e
 among current drinkers; ǂ Not evaluated; Generalized linear models adjusted for: age (continuous), fasting status ((<3, 3-6, >6 hours, missing), time of day 
(continuous), and menstrual cycle phase at blood collection (premenopausal women: early follicular, late follicular, ovulatory, early luteal, mid luteal, late luteal, missing), and country. 
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Table 3.  Cross-sectional associations between reproductive characteristics and OPG concentrations (geometric means; pmol/L) by menopausal 
status and PMH use at blood collection. 
 Premenopausal women  
Postmenopausal women  
 
No PMH PMH  
 n (%)
a Geometric mean 
(95%CI) 
n (%)
a Geometric mean 
(95%CI) 
n (%)
a Geometric mean 
(95%CI) 
Full study population* 464 (100%) 9.48 (9.08-9.91) 795 (100%) 9.80 (9.48-10.14) 757 (100%) 10.25 (9.88-10.63) 
Age at blood collection, years       
<50 370 (80) 8.11  (7.64-8.60) 13 (2%) 8.55 (7.36-9.92) 31 (4%) 8.60 (7.80-9.49) 
50-54 91 (19) 9.38  (7.75-9.10) 127 (16%) 8.80 (8.29-9.35) 194 (26%) 9.36 (8.86-9.88) 
55-59 3 (1) ǂ 292 (37%) 9.70 (9.18-10.24) 308 (41%) 9.31 (8.82-9.82) 
60+   363 (46%) 10.84  (10.30-11.40) 224 (30%) 10.60 (10.01-11.23) 
Ptrend
b
  0.01  <0.01  <0.01 
Age at menarche       
     <12 years 80 (17%) 7.84 (7.28-8.45) 104 (13%) 10.21 (9.54-10.93) 120 (16%) 9.49 (8.93-10.10) 
     12-14 years 322 (70%) 8.14 (7.68-8.63) 517 (66%) 9.89 (9.42-10.37) 483 (64%) 9.76 (9.27-10.27) 
     ≥15 years 59 (13%) 8.22 (7.59-8.90) 163 (21%) 10.11 (9.53-10.71) 146 (19%) 9.78 (9.19-10.41) 
Ptrend
b
  0.18  0.23  0.16 
Oral contraceptive (OC) use       
     Never 166 (37%) 7.88 (7.39-8.40) 495 (65%) 9.92 (9.45-10.41) 282 (41%) 9.34 (8.83-9.89) 
          < 5 years 157 (35%) 8.18 (7.68-8.72) 134 (18%) 10.13 (9.52-10.78) 164 (24%) 9.56 (8.99-10.16) 
          5-9 years 75 (17%) 8.19 (7.59-8.85) 51 (7%) 9.60 (8.81-10.47) 78 (11%) 9.70 (9.01-10.45) 
          ≥ 10 years 47 (11%) 8.46 (7.77-9.22) 81 (11%) 10.23 (9.50-11.01) 168 (24%) 10.15 (9.53-10.81) 
Ptrend
c
 including never users  0.04  0.64  <0.01 
Ptrend
bd
 among ever users
 
 0.38  0.86  0.07 
Full-term pregnancy (FTP)       
     Never 57 (12%) 7.98 (7.33-8.69) 102 (13%) 10.34 (9.69-11.04) 88 (12%) 9.53 (8.90-10.20) 
     Ever 401 (86%) 8.15 (7.66-8.67) 691 (87%) 9.92 (9.47-10.39) 647 (85%) 9.72 (9.26-10.21) 
          1 FTP 85 (21%) 8.24 (7.57-8.97) 110 (16%) 9.53 (8.91-10.21) 120 (19%) 9.78 (9.17-10.43) 
          2 FTPs 216 (54%) 8.13 (7.55-8.75) 317 (46%) 10.03 (9.51-10.58) 316 (49%) 9.64 (9.15-10.17) 
          ≥ 3 FTPs  99 (25%) 8.33 (7.71-8.99) 264 (38%) 9.88 (9.35-10.44) 210 (32%) 9.68 (9.14-10.25) 
Pcat
c
 ever/never FTP  0.54  0.13  0.46 
Pcat
ce
 number of FTP
 
 0.66  0.22  0.86 
Age at first FTP
e
       
     < 25 years 191 (48%) 8.30 (7.72-8.92) 318 (46%) 9.83 (9.33-10.36) 369 (57%) 9.74 (9.24-10.27) 
     ≥ 25 years 208 (52%) 8.03 (7.46-8.64) 371 (54%) 9.98 (9.45-10.54) 272 (42%) 9.85 (9.32-10.40) 
Ptrend
b
  0.11  0.26  0.65 
a
 percentages may not add up to 100% due to missing data; 
b
 P value for linear trend assessed using type III F statistics from linear regression models with continuous exposure variables; 
c
 
P value for difference in geometric mean concentration of OPG across categories of the exposure variable. Assessed using type III F statistics from linear regression models; 
d
 among 
those who ever used OCs; 
e
 Among those who ever had a FTP; ǂ Not applicable; Generalized linear models adjusted for: age (continuous), fasting status ((<3, 3-6, >6 hours, missing), time 
of day (continuous), and menstrual cycle phase at blood collection (premenopausal women: early follicular, late follicular, ovulatory, early luteal, mid luteal, late luteal, missing), and 
country.*P value comparing pre- to postmenopausal at blood collection=0.57; comparing PMH to no PMH use at blood collection <0.01. 
on August 1, 2019. © 2019 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 10, 2019; DOI: 10.1158/1055-9965.EPI-19-0241 
 Page 19 of 20 
 
 
Table 4.  Cross-sectional associations between lifestyle characteristics and OPG concentrations (geometric means; pmol/L) by menopausal status 
and PMH use at blood collection. 
 Premenopausal women  
Postmenopausal women  
 
No PMH PMH  
 n (%)
a Geometric mean 
(95%CI) 
n (%)
a Geometric mean 
(95%CI) 
n (%)
a Geometric mean 
(95%CI) 
Baseline BMI       
    < 20 kg/m
2
 29 (6%) 7.76 (7.01-8.59) 48 (6%) 10.18 (9.35-11.09) 64 (8%) 10.31 (9.55-11.12) 
     20-24.9 kg/m
2
 252 (54%) 8.17 (7.69-8.67) 336 (42%) 9.98 (9.49-10.51) 426 (56%) 9.72 (9.23-10.23) 
     25-29.9 kg/m
2
 138 (30%) 8.10 (7.59-8.66) 299 (38%) 9.82 (9.32-10.35) 214 (28%) 9.612 (9.09-10.17) 
    ≥ 30 kg/m
2
 45 (10%) 8.09 (7.41-8.83) 112 (14%) 10.16 (9.53-10.82) 53 (7%) 9.41 (8.69-10.19) 
Ptrend
b
  0.74  0.60  0.23 
Baseline smoking status       
     Never smoker 247 (53%) 8.00 (7.53-8.50) 463 (58%) 9.94 (9.47-10.44) 395 (52%) 9.70 (9.21-10.22) 
     Former smoker 110 (52%) 8.18 (7.66-8.75) 181 (56%) 9.88 (9.33-10.45) 198 (59%) 9.62 (9.09-10.17) 
     Current smoker 102 (48%) 8.40 (7.83-9.00) 144 (44%) 10.27 (9.65-10.93) 138 (41%) 9.95 (9.35-10.59) 
          ≤ 10 years
c
 45 (21%) 7.73 (7.04-8.49) 42 (13%) 9.88 (8.75-11.15) 55 (16%) 9.91 (8.93-11.01) 
          11-20 years
c
 62 (29%) 7.86 (7.18-8.60) 44 (14%) 10.44 (9.24-11.78) 50 (15%) 9.23 (8.25-10.31) 
          21-30 years
c
 86 (41%) 8.41 (7.73-9.16) 68 (21%) 10.03  (9.04-11.12) 73 (22%) 9.45 (8.54-10.46) 
          31-40 years
c
 13 (6%) 7.41 (6.41-8.57) 92 (28%) 10.97 (9.88-12.19) 94 (28%) 10.07 (9.11-11.14) 
          > 40 years
c
 0 ǂ 60 (18%) 9.90 (8.84-11.08) 41 (12%) 10.43 (9.22-11.81) 
Pcat
d
 never vs. current smoking 0.09  0.20  0.33 
Ptrend
bc
 duration of smoking
 
 0.36  0.59  0.20 
Baseline physical activity       
     Inactive 75 (16%) 8.08 (7.49-8.72) 82 (10%) 9.82 (9.12-10.57) 148 (20%) 9.47 (8.89-10.10) 
     Moderately inactive 145 (31%) 8.03 (7.54-8.56) 247 (31%) 9.88 (9.34-10.44) 319 (42%) 9.75 (9.21-10.31) 
     Moderately active 193 (42%) 8.39 (7.86-8.94) 405 (51%) 10.00 (9.53-10.50) 230 (30%) 9.77 (9.26-10.30) 
     Active 51 (11%) 8.86 (7.26-8.52) 61 (8%) 10.25 (9.48-11.09) 59 (8%) 9.57 (8.87-10.34) 
Pcat
d 
inactive vs. active  0.52  0.33  0.78 
Lifetime alcohol consumption      
   Non-drinker 41 (9%) 8.04 (7.28-8.87) 88 (11%) 10.64 (9.87-11.47) 27 (4%) 10.40 (9.35-11.57) 
   Former drinker 15 (3%) 7.99 (6.95-9.18) 49 (6%) 11.13 (10.16-12.19) 12 (2%) 10.01 (8.67-11.55) 
   Current drinker 395 (85%) 8.11 (7.55-8.70) 639 (80%) 10.25 (9.69-10.84) 696 (93%) 9.87 (9.36-10.40) 
      < 6 gram/day
e 
144 (31%) 8.23 (7.60-8.90) 219 (28%) 10.13 (9.52-10.78) 181 (24%) 10.01 (9.42-10.64) 
      6-12 gram/day
e 
168 (36%) 8.00 (7.42-8.62) 305 (38%) 10.36 (9.75-11.02) 337 (45%) 9.74 (9.21-10.30) 
      ≥12 gram day
e 
83 (18%) 8.18 (7.53-8.89) 115 (14%) 1027 (9.57-11.02) 178 (24%) 9.95 (9.36-10.57) 
Pcat
d
 never vs. current alcohol use  0.83  0.22  0.27 
Ptrend
b
 gram/day
e 
 0.88  0.41  0.66 
a
 percentages may not add up to 100% due to missing data; 
b
 P value for linear trend assessed using type III F statistics from linear regression models with continuous exposure variables; 
c
 Among current and former smokers; 
d
 P value for difference in geometric mean concentration of OPG across categories of the exposure variable. Assessed using type III F statistics from 
linear regression models; 
e
 Among current drinkers; 
 
ǂ Not applicable; Generalized linear models adjusted for: age (continuous), fasting status ((<3, 3-6, >6 hours, missing), time of day 
(continuous), and menstrual cycle phase at blood collection (premenopausal women: early follicular, late follicular, ovulatory, early luteal, mid luteal, late luteal, missing), and country. 
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Figure legend 
Figure 1. Overview of participants from the parent case-control study who were eligible for the current 
study and in whom sRANKL and OPG concentrations were measured. Abbreviations: EPIC: European 
Prospective Investigation into Cancer and Nutrition; LLOD: Lower Limit of Detection; OPG: 
Osteoprotegerin; sRANKL: soluble Receptor Activator of Nuclear Factor kB. 
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